Cervical Squamous Intraepithelial Neoplasia 2 clinical trials at University of California Health
1 in progress, 0 open to eligible people
Showing trials for
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Sorry, in progress, not accepting new patients
This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
at UCLA
Our lead scientists for Cervical Squamous Intraepithelial Neoplasia 2 research studies include John A Glaspy, MD.
Last updated: